Curebase, which manages software and hardware for distributed clinical trials, raises a $40M Series B led by Industry Ventures
physical and digital — for distributed clinical trials, accelerating quality medical innovations to patients through more efficient clinical studies: https://techcrunch.com/...
Context & Ripple Effects
Curebase's raise lands in the middle of a sustained capital wave around clinical-trial software. Medable set the pace, going from a $91M Series C tied to COVID-19 vaccine development to a $304M Series D at a $2.1B valuation, while Castor's $45M Series B and Reify Health's $30M Series B showed mid-market investors funding the same thesis at smaller checks.
What separates Curebase from that cohort is scope: it manages both software and hardware for distributed trials, meaning sites, devices, and data capture rather than trial software alone. Industry Ventures leading the round puts it in direct competition with far larger rivals for sponsor budgets.
First-order effects
- Curebase gains $40M to scale its combined software-and-hardware platform for distributed trials, competing against Medable's $2.1B-valued stack and Castor's trial software for the same sponsors.
Second-order effects
- Sponsors evaluating decentralized trial vendors now have a hardware-inclusive option, pressuring software-only players like Castor and Medable to match full-stack offerings or cede the distributed-trial niche.
Third-order effects
- If the funding pattern holds, clinical trial execution consolidates around capitalized platforms that own the full data path from device to record, squeezing smaller single-tool vendors and shifting trial infrastructure toward decentralized, site-agnostic models.
The trend: Clinical trial software is drawing successive funding rounds of increasing size as decentralized, platform-based trial infrastructure replaces site-bound study models.